

ANIKA Therapeutics, Inc.

32 Wiggins Avenue,
Bedford, MA, 01730, United States

Device Identification:
Cingal®

Intended Purpose of Device:
Sterile viscoelastic supplement or replacement for synovial fluid in human joints with triamcinolone hexacetonide for short term pain relief.

has been assessed and certified as meeting the requirements of

Directive 93/42/EEC on Medical Devices Annex II, section 4

It is certified that the manufacturer's design dossier (and product, where applicable) for the above device has been examined and, based on the evidence submitted, it is considered that the device conforms to the relevant Essential Requirements of EC Directive 93/42/EEC.

This certificate is issued in conjunction with a certificate covering the full quality assurance system to Annex II, which must be subject to satisfactory surveillance audits.

This certificate is valid from 24 March 2016 until 24 March 2021
Issue 1

Certification is based on report number(s) WW/ME 603224 dated 14 April 2015

Addenda to that report have been issued on the following dates:

<u>Addendum Date</u>	<u>Reason for Addendum</u>
----------------------	----------------------------


Authorised by

SGS United Kingdom Limited, Notified Body 0120

202B Worle Parkway, Weston-super-Mare, BS22 6WA, UK
t +44 (0)1934 522917 f +44 (0)1934 522137 www.sgs.com

SGS EC 01 0311

Page 1 of 1



This document is issued by the Company subject to its General Conditions of Certification Services accessible at www.sgs.com/terms_and_conditions.htm. Attention is drawn to the limitations of liability, indemnification and jurisdictional issues established therein. The authenticity of this document may be verified at <http://www.sgs.com/en/Our-Company/Certified-Client-Directories/Certified-Client-Directories.aspx>. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.